| 纯度 | >90%SDS-PAGE. |
| 种属 | Escherichia |
| 靶点 | RELB |
| Uniprot No | P0C079 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-79aa |
| 氨基酸序列 | MGSINLRIDDELKARSYAALEKMGVTPSEALRLMLEYIADNERLPFKQTLLSDEDAELVEIVKERLRNPKPVRVTLDEL |
| 预测分子量 | 16.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RELB重组蛋白的3篇参考文献示例(注：以下内容为示例性概括，非真实文献)：
1. **"Structural and Functional Characterization of Recombinant RELB Protein in NF-κB Signaling"**
*作者：Smith A, et al.*
**摘要**：本研究通过大肠杆菌系统成功表达并纯化了重组RELB蛋白，解析了其与p52亚基形成的二聚体结构，揭示了其在非经典NF-κB通路中的激活机制。
2. **"RELB Recombinant Protein Modulates Inflammatory Responses in Macrophages"**
*作者：Chen L, et al.*
**摘要**：利用哺乳动物细胞表达的重组RELB蛋白，研究发现其通过调控IL-6和TNF-α的分泌参与巨噬细胞炎症反应，为治疗自身免疫疾病提供潜在靶点。
3. **"High-Yield Production of Human RELB in Insect Cells and Its Role in Cancer Cell Survival"**
*作者：Wang Y, et al.*
**摘要**：通过杆状病毒-昆虫细胞系统高效表达人源RELB重组蛋白，证实其通过激活BCL-2通路促进淋巴瘤细胞存活，提示其在肿瘤治疗中的研究价值。
4. **"RELB/p52 Dimer-Specific Inhibitors Identified Using Recombinant Protein Screening"**
*作者：Johnson R, et al.*
**摘要**：基于重组RELB/p52蛋白的高通量筛选平台，发现新型小分子抑制剂可选择性阻断二聚体活性，为靶向NF-κB通路的药物开发提供工具。
(注：以上文献信息为模拟示例，实际引用请查询权威数据库如PubMed。)
**Background of RELB Recombinant Protein**
RELB (RELB Proto-Oncogene) is a member of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) family of transcription factors, which play pivotal roles in immune regulation, inflammation, cell survival, and differentiation. Structurally, RELB contains a conserved N-terminal Rel homology domain (RHD) responsible for DNA binding and dimerization, and a C-terminal transactivation domain. Unlike other NF-κB members (e.g., RELA/p65), RELB primarily functions in the non-canonical NF-κB signaling pathway. It forms heterodimers with NF-κB2/p100 (processed to p52) to regulate gene expression in response to stimuli like lymphotoxin-β, CD40 ligand, or BAFF.
RELB recombinant protein is engineered through molecular cloning, often expressed in *E. coli* or mammalian systems, followed by purification to ensure biological activity. This protein is widely used in research to study NF-κB signaling mechanisms, immune cell development (e.g., dendritic cells, B cells), and inflammatory diseases. Its aberrant activation or mutations are linked to cancers (e.g., lymphoma, multiple myeloma) and autoimmune disorders.
In therapeutic contexts, RELB recombinant protein aids in screening inhibitors targeting NF-κB pathways or developing gene therapies. However, challenges remain in understanding its context-dependent roles and tissue-specific regulation. Overall, RELB serves as a critical tool for dissecting immune and inflammatory processes, offering potential avenues for disease intervention.
×
